Grail reports NHS-Galleri trial results showing reduced Stage IV cancer diagnoses

Reuters

Feb 20

Grail reports NHS-Galleri trial results showing reduced Stage IV cancer diagnoses

Grail Inc. announced topline results from the randomized, controlled NHS-Galleri trial evaluating annual multi-cancer screening with its Galleri test in 142,000 participants aged 50–77 in England’s NHS over three years. The trial did not meet its primary endpoint of a statistically significant combined Stage III–IV reduction, but reported reductions in Stage IV diagnoses over sequential screening rounds (including greater than 20% reductions in rounds two and three) in a pre-specified group of 12 cancers, along with increased detection of Stage I–II cancers and a four-fold improvement in overall cancer detection rate versus standard screening alone. Detailed results have not yet been presented and are planned for submission for presentation at the ASCO 2026 Annual Meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grail Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602191601PR_NEWS_USPR_____LA91803) on February 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612238878"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612238878\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612238878?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 05:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612238878","market":"us","top_or_hot":-1,"title":"Grail reports NHS-Galleri trial results showing reduced Stage IV cancer diagnoses","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Grail reports NHS-Galleri trial results showing reduced Stage IV cancer diagnoses\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Grail Inc. announced topline results from the randomized, controlled NHS-Galleri trial evaluating annual multi-cancer screening with its Galleri test in 142,000 participants aged 50–77 in England’s NHS over three years. The trial did not meet its primary endpoint of a statistically significant combined Stage III–IV reduction, but reported reductions in Stage IV diagnoses over sequential screening rounds (including greater than 20% reductions in rounds two and three) in a pre-specified group of 12 cancers, along with increased detection of Stage I–II cancers and a four-fold improvement in overall cancer detection rate versus standard screening alone. Detailed results have not yet been presented and are planned for submission for presentation at the ASCO 2026 Annual Meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grail Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602191601PR_NEWS_USPR_____LA91803) on February 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grail reports NHS-Galleri trial results showing reduced Stage IV cancer diagnoses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrail reports NHS-Galleri trial results showing reduced Stage IV cancer diagnoses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-20 05:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Grail reports NHS-Galleri trial results showing reduced Stage IV cancer diagnoses\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Grail Inc. announced topline results from the randomized, controlled NHS-Galleri trial evaluating annual multi-cancer screening with its Galleri test in 142,000 participants aged 50–77 in England’s NHS over three years. The trial did not meet its primary endpoint of a statistically significant combined Stage III–IV reduction, but reported reductions in Stage IV diagnoses over sequential screening rounds (including greater than 20% reductions in rounds two and three) in a pre-specified group of 12 cancers, along with increased detection of Stage I–II cancers and a four-fold improvement in overall cancer detection rate versus standard screening alone. Detailed results have not yet been presented and are planned for submission for presentation at the ASCO 2026 Annual Meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grail Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602191601PR_NEWS_USPR_____LA91803) on February 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL82JSK4:1","article_id":"2612238878","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612238878","pubTimestamp":1771534897,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Grail Inc. announced topline results from the randomized, controlled NHS-Galleri trial evaluating annual multi-cancer screening with its Galleri test in 142,000 participants aged 50–77 in England’s NHS over three years. The trial did not meet its primary endpoint of a statistically significant combined Stage III–IV reduction, but reported reductions in Stage IV diagnoses over sequential screening rounds  in a pre-specified group of 12 cancers, along with increased detection of Stage I–II cancers and a four-fold improvement in overall cancer detection rate versus standard screening alone. Detailed results have not yet been presented and are planned for submission for presentation at the ASCO 2026 Annual Meeting.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GRAL":"GRAIL, Inc."},"translate_title":"Grail报告NHS-Galleri试验结果显示IV期癌症诊断减少","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRAL":0.9},"content_text":"Grail reports NHS-Galleri trial results showing reduced Stage IV cancer diagnoses\n    \n\n        Grail Inc. announced topline results from the randomized, controlled NHS-Galleri trial evaluating annual multi-cancer screening with its Galleri test in 142,000 participants aged 50–77 in England’s NHS over three years. The trial did not meet its primary endpoint of a statistically significant combined Stage III–IV reduction, but reported reductions in Stage IV diagnoses over sequential screening rounds (including greater than 20% reductions in rounds two and three) in a pre-specified group of 12 cancers, along with increased detection of Stage I–II cancers and a four-fold improvement in overall cancer detection rate versus standard screening alone. Detailed results have not yet been presented and are planned for submission for presentation at the ASCO 2026 Annual Meeting.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grail Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602191601PR_NEWS_USPR_____LA91803) on February 19, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}